A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
Completed · Phase 3 · NCT05027802
Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
At a glance
- Research payments reported, 2025
- $2,343
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 61
About the trial
- Sponsor
- Ipsen
- Tested
- Palovarotene (drug)
- Dates
- Started 2022-03-14; completion 2024-11-30
- Results posted
- Yes
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.
From ClinicalTrials.gov, last updated 2025-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Pharma Sas reported $2,343 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $2,000
- Mayo Clinic $343
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.